Topalgic (France)


Indications and Reactions:

Role Indications Reactions
Secondary
Drug Use For Unknown Indication 34.1%
Product Used For Unknown Indication 15.9%
Pain 14.4%
Chemotherapy 3.8%
Abdominal Pain 3.4%
Chronic Obstructive Pulmonary Disease 3.4%
Cauda Equina Syndrome 2.9%
Postoperative Care 2.9%
Herpes Zoster 2.4%
Osteoporosis 2.4%
Breast Cancer Metastatic 1.9%
Extragonadal Primary Germ Cell Tumour Mixed Stage I 1.9%
Febrile Bone Marrow Aplasia 1.9%
Prophylaxis 1.9%
Hypertension 1.4%
Type 2 Diabetes Mellitus 1.4%
Cerebral Toxoplasmosis 1.0%
Eczema 1.0%
General Anaesthesia 1.0%
Nausea 1.0%
Vomiting 13.9%
Respiratory Failure 11.1%
Skin Exfoliation 8.3%
Urinary Incontinence 8.3%
Interstitial Lung Disease 5.6%
Pneumatosis Intestinalis 5.6%
Respiratory Distress 5.6%
Tachycardia 5.6%
Vascular Purpura 5.6%
Gaze Palsy 2.8%
Hepatitis Fulminant 2.8%
Hepatocellular Injury 2.8%
Hypotension 2.8%
Leukopenia 2.8%
Malaise 2.8%
Neutropenia 2.8%
Rash Vesicular 2.8%
Sepsis 2.8%
Shock 2.8%
Shock Haemorrhagic 2.8%
Concomitant
Drug Use For Unknown Indication 55.8%
Product Used For Unknown Indication 7.4%
Hiv Infection 4.1%
Thrombosis Prophylaxis 4.1%
Pain 3.8%
Erysipelas 3.2%
Sepsis 2.7%
Phlebitis 2.1%
Hypertension 1.8%
Musculoskeletal Chest Pain 1.8%
Preoperative Care 1.8%
Antibiotic Prophylaxis 1.5%
Prophylaxis Of Nausea And Vomiting 1.5%
Sleep Disorder 1.5%
Colorectal Cancer 1.2%
Herpes Zoster 1.2%
Influenza Like Illness 1.2%
Lymphoma 1.2%
Osteitis 1.2%
Prophylaxis 1.2%
Toxic Skin Eruption 16.4%
Sepsis 9.0%
Neutropenia 6.0%
Shock 6.0%
Thrombocytopenia 6.0%
Vomiting 6.0%
Intentional Drug Misuse 4.5%
Platelet Count Increased 4.5%
Renal Failure 4.5%
Respiratory Failure 4.5%
Thrombosis 4.5%
Visual Impairment 4.5%
Haematoma 3.0%
Hepatocellular Injury 3.0%
Overdose 3.0%
Pharmaceutical Product Complaint 3.0%
Pneumothorax 3.0%
Prothrombin Time Ratio Decreased 3.0%
Pulmonary Haemorrhage 3.0%
Sudden Onset Of Sleep 3.0%

Drug Data